Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Feb-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2024 . | Download
EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Feb-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2024 . | Download
Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 23, 2025, titled "Emcure Pharmaceuticals Inaugurates World-class R&D centre in Gujarat". | Download
Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 23, 2025, titled "Emcure Pharmaceuticals Inaugurates World-class R&D centre in Gujarat". | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant